-
公开(公告)号：US11208633B2
公开(公告)日：2021-12-28
申请号：US16704744
申请日：2019-12-05
Applicant: Pfizer Inc.
Inventor： Jason Arnold Lotvin , Annaliesa Sybil Anderson , Robert G. K. Donald , Michael James Flint , Narender Kumar Kalyan , Kathrin Ute Jansen , Maninder K. Sidhu , Justin Keith Moran , Mark Edward Ruppen , Weiqiang Sun
Abstract: In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. The mutant toxin may include a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to methods and compositions for use in culturing Clostridium difficile and in producing C. difficile toxins.
-
公开(公告)号：US20220168410A1
公开(公告)日：2022-06-02
申请号：US17672126
申请日：2022-02-15
Applicant: Pfizer Inc.
Inventor： Robert G.K. Donald , Annaliesa Sybil Anderson , Laurent Oliver Chorro , Jianxin Gu , Jin-Hwan Kim , Srinivas Kodali , Jason Arnold Lotvin , Justin Keith Moran , Rosalind Pan , Avvari Krishna Prasad , Mark Edward Ruppen , Suddham Singh , Ling Chu , Scott Ellis Lomberk , Karen Kiyoko Takane , Nishith Merchant , Wei Chen
IPC: A61K39/108 , C08B37/00 , A61P31/04 , A61P37/04
Abstract: In one aspect, the invention relates to an immunogenic composition comprising modified O-polysaccharide molecules derived from E. coli lipopolysaccharides and conjugates thereof. Multivalent vaccines may be prepared by combining two or more monovalent immunogenic compositions for different E. coli serotypes. In one embodiment, the modified O-polysaccharide molecules are produced by a recombinant bacterium that includes a wzz gene.
-
公开(公告)号：US20210180008A1
公开(公告)日：2021-06-17
申请号：US17170036
申请日：2021-02-08
Applicant: Pfizer Inc.
Inventor： Sunil Gururao Desai , Michael Allen Hanson , Jonathan Patrick Kinross , Daniel R. Lasko , Scott Ellis Lomberk , Jason Arnold Lotvin , Sujata Kaushikbhai Patel-Brown , Weiqiang Sun , Peter Anthony Tomasello
Abstract: The present invention relates to media and fermentation methods for producing polysaccharides in bacterial cell culture. In one aspect, the invention relates to a complex culture medium comprising a vegetable hydrolysate, a yeast extract, and a carbon source. In another aspect, the invention relates to a defined media having a total amino acid concentration greater than about 50 mM. A further aspect of the invention relates to the use of fed batch and perfusion fermentation methods for cultivating polysaccharide-producing bacteria.
-
4.发明申请公开(公告)号：US20190292513A1
公开(公告)日：2019-09-26
申请号：US15775172
申请日：2016-11-10
Applicant: Pfizer Inc.
Inventor： Sunil Gururao Desai , Michael Allen Hanson , Jonathan Patrick Kinross , Daniel R. Lasko , Scott Ellis Lomberk , Jason Arnold Lotvin , Sujata Kaushikbhai Patel-Brown , Weiqiang Sun , Peter Anthony Tomasello
Abstract: The present invention relates to media and fermentation methods for producing polysaccharides in bacterial cell culture. In one aspect, the invention relates to a complex culture medium comprising a vegetable hydrolysate, a yeast extract, and a carbon source. In another aspect, the invention relates to a defined media having a total amino acid concentration greater than about 50 mM. A further aspect of the invention relates to the use of fed batch and perfusion fermentation methods for cultivating polysaccharide-producing bacteria.
-
5.发明申请公开(公告)号：US20150291940A1
公开(公告)日：2015-10-15
申请号：US14436875
申请日：2013-10-07
Applicant: PFIZER INC.
Inventor： Jason Arnold Lotvin , Annaliesa Sybil Anderson , Robert G. K. Donald , Michael James Flint , Narender Kumar Kalyan , Kathrin Ute Jansen , Maninder K. Sidhu , Justin Keith Moran , Mark Edward Ruppen , Weiqiang Sun
IPC: C12N9/10
Abstract: In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. The mutant toxin may include a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to methods and compositions for use in culturing Clostridium difficile and in producing C. difficile toxins.
Abstract translation: 一方面，本发明涉及包含突变型艰难梭菌毒素A和/或突变型艰难梭菌毒素B的免疫原性组合物。突变毒素可以包括具有至少一个突变的葡糖基转移酶结构域和至少具有至少一个突变的半胱氨酸蛋白酶结构域 一个突变，相对于相应的野生型艰难梭菌毒素。 突变毒素可以包括至少一个化学交联的氨基酸。 另一方面，本发明涉及用于培养艰难梭菌和产生艰难梭菌毒素的方法和组合物。
-
Patent Agency Ranking
公开(公告)号：US20250002875A1
公开(公告)日：2025-01-02
申请号：US18593348
申请日：2024-03-01
Applicant: Pfizer Inc.
Inventor： Jason Arnold Lotvin , Annaliesa Sybil Anderson , Robert G. K. Donald , Michael James Flint , Narender Kumar Kalyan , Kathrin Ute Jansen , Maninder K. Sidhu , Justin Keith Moran , Mark Edward Ruppen , Weiqiang Sun
Abstract: In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. The mutant toxin may include a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to methods and compositions for use in culturing Clostridium difficile and in producing C. difficile toxins.
-
公开(公告)号：US20200165582A1
公开(公告)日：2020-05-28
申请号：US16704744
申请日：2019-12-05
Applicant: Pfizer Inc.
Inventor： Jason Arnold Lotvin , Annaliesa Sybil Anderson , Robert G.K. Donald , Michael James Flint , Narender Kumar Kalyan , Kathrin Ute Jansen , Maninder K. Sidhu , Justin Keith Moran , Mark Edward Ruppen , Weiqiang Sun
Abstract: In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. The mutant toxin may include a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to methods and compositions for use in culturing Clostridium difficile and in producing C. difficile toxins.
-
公开(公告)号：US20190112584A1
公开(公告)日：2019-04-18
申请号：US16104938
申请日：2018-08-19
Applicant: Pfizer Inc.
Inventor： Jason Arnold Lotvin , Annaliesa Sybil Anderson , Robert G. K. Donald , Michael James Flint , Narender Kumar Kalyan , Kathrin Ute Jansen , Maninder K. Sidhu , Justin Keith Moran , Mark Edward Ruppen , Weiqiang Sun
Abstract: In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. The mutant toxin may include a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to methods and compositions for use in culturing Clostridium difficile and in producing C. difficile toxins.
-
公开(公告)号：US11952597B2
公开(公告)日：2024-04-09
申请号：US16922952
申请日：2020-07-07
Applicant: Pfizer Inc.
Inventor： Jason Arnold Lotvin , Annaliesa Sybil Anderson , Robert G. K. Donald , Michael James Flint , Narender Kumar Kalyan , Kathrin Ute Jansen , Maninder K. Sidhu , Justin Keith Moran , Mark Edward Ruppen , Weiqiang Sun
CPC classification number: C12N9/1051 , C07K14/33 , C12N1/20
Abstract: In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. The mutant toxin may include a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to methods and compositions for use in culturing Clostridium difficile and in producing C. difficile toxins.
-
10.发明公开公开(公告)号：US20230405137A1
公开(公告)日：2023-12-21
申请号：US18252124
申请日：2021-11-04
Applicant: Pfizer Inc.
Inventor： Paul Wayne Brown , Kaushik Dutta , Jason Arnold Lotvin , Kelly Jeffrey Sackett
CPC classification number: A61K47/646 , A61K39/092 , A61P31/04 , A61K2039/6037
Abstract: The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates), kits comprising said immunogenic compositions and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR®, SYNFLORIX® and/or PREVNAR 13®. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumococcal infections using said novel immunogenic compositions.
-
-
-
-
-
-
-
-
-
Search Results
19
records
(took 0.02 seconds)
